Skip to main content
. Author manuscript; available in PMC: 2014 Dec 15.
Published in final edited form as: Toxicol Appl Pharmacol. 2013 Oct 3;273(3):10.1016/j.taap.2013.09.023. doi: 10.1016/j.taap.2013.09.023

Figure 3.

Figure 3

Full length (FL-K18) and caspase-cleaved (cK18) cytokeratin-18 levels in plasma after galactosamine/endotoxin (Gal/End) treatment, bile duct ligation (BDL) or sham-operation. The values of sham-operation (<150 pmol/ml) were subtracted from the BDL values. Data represent mean ± SE of n=4–6 animals per group. *P<0.05 (compared to untreated control); #P<0.05 (compared to cK18 values)